Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

Starting soon · Phase 4

Conditions studied: Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild

In brief

This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of seizures, stroke, and even death. Over 60% of patients with preeclampsia continue to experience high blood pressure at the time of discharge from their delivery hospitalization, and many of these patients require blood pressure medications for up to 6 months postpartum. Even with blood pressure medications, many of these patients are readmitted to the hospital within six weeks of delivery. In this study, the investigators will utilize point-of-care ultrasound (POCUS), a quick and non-invasive, bedside imaging strategy, to look for signs of excess fluid accumulating in the lungs and venous system of postpartum patients with preeclampsia. Because excess fluid has the potential to worsen blood pressure, subjects with evidence of this on POCUS would be treated with a diuretic medication called furosemide (either orally or intravenously) within 24 hours of delivery. The investigators' main goal is to determine whether using POCUS can help physicians make better treatment decisions and improve short-term outcomes for postpartum patients with preeclampsia. The investigators' aim to achieve faster recovery of blood pressure, reduce the need for blood pressure medication at hospital discharge, and lower the rates of hospital readmission for those with preeclampsia. This study could significantly enhance the overall care and health of postpartum patients.

Key facts

Study ID: NCT07167862
Run by: University of California, Irvine
People needed: 96
Starts: 2026-06-15
Expected to finish: 2028-06-15
Last updated by the study team: 2026-01-23

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Historical cohort (group 1):
Age greater than or equal to 18 years at the time of delivery
Diagnosis of preeclampsia (without severe features, with severe features, HELLP syndrome, eclampsia) during pregnancy
Gestational age greater than or equal to 20 weeks' gestation at delivery
Delivery at the study institution within the 18-month period prior to implementation of the study's POCUS intervention
Available and complete postpartum clinical data on: Daily blood pressure, diuretic or antihypertensive use, length of postpartum hospital stay, readmission within 30 days of primary hospitalization
Prospective cohorts (groups 2 and 3):
Age greater than or equal to 18 years at the time of enrollment
Diagnosis of preeclampsia (without severe features, with severe features, HELLP syndrome, eclampsia) made up until 24 hours postpartum Postpartum and within 24 hours of delivery

You may not qualify if…

Historical cohort (group 1):
Delivery at an outside facility or incomplete postpartum records available for analysis
Pre-existing diagnosis of chronic hypertension; selected to mirror prospective cohort exclusion criteria (see below).
Documentation of chronic kidney disease (CKD stage 3 or higher); selected because diuresis is more likely to be avoided in this patient population even in the presence of physical exam findings suggesting volume overload.
Documentation of postpartum complications unrelated to preeclampsia that may significantly alter hemodynamics (e.g., sepsis, postpartum hemorrhage); selected because diuresis is more likely to be avoided in this patient population even in the presence of physical exam findings suggesting volume overload.
Prospective cohorts (groups 2 and 3):
Pre-existing diagnosis of chronic hypertension; selected because previous studies on furosemide use in patients with postpartum preeclampsia have found a significant reduction in hypertension among patients with newly diagnosed hypertensive disorders of pregnancy, but not among those with pre-gestational hypertension, meaning that inclusion of this population might reduce the magnitude of study effects.
Baseline renal dysfunction with serum creatinine > 1.1 mg/dL; selected as this laboratory finding has been pre-selected as a safety outcome.
Baseline hypokalemia with serum potassium < 3.5 mEq/L despite previous repletion with intravenous or oral potassium chloride; selected as this laboratory finding has been pre-selected as a safety outcome.
Known hypersensitivity to furosemide or sulfa drugs; selected because this would preclude exposure to the study medication of interest.
Current use of diuretics for other indications (e.g. heart failure); selected because this may require a furosemide or other diuretic regimen different from that planned for the study intervention.

Where it is running

University of California Irvine Medical Center — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.